Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture

[1] Hadji P(2013)The epidemiology of osteoporosis—Bone Evaluation Study (BEST): an analysis of routine health insurance data Dtsch Ärztebl Int 110 52-57

[2] Klein S(2013)Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch Osteoporos 8 136-300

[3] Gothe H(2011)Current, new and future treatments of osteoporosis Rheumatol Int 31 289-2051

[4] Häussler B(2006)Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis Can Med Assoc J 175 48-746

[5] Kless T(2012)Bisphosphonates for osteoporosis—where do we go from here? N Engl J Med 366 2048-1352

[6] Schmidt T(2004)Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography Bone 34 736-1199

[7] Steinle T(1999)Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group JAMA 282 1344-638

[8] Verheyen F(2004)Ten years’ experience with alendronate for osteoporosis in postmenopausal women N Engl J Med 350 1189-176

[9] Linder R(2008)Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women Cochrane Database Syst Rev 84 632-1841

[10] Hernlund E(2009)Adverse effects of bisphosphonates: implications for osteoporosis management Mayo Clin Proc 93 165-765

[1] Hadji P(2013)The epidemiology of osteoporosis—Bone Evaluation Study (BEST): an analysis of routine health insurance data Dtsch Ärztebl Int 110 52-57

[2] Klein S(2013)Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch Osteoporos 8 136-300

[3] Gothe H(2011)Current, new and future treatments of osteoporosis Rheumatol Int 31 289-2051

[4] Häussler B(2006)Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis Can Med Assoc J 175 48-746

[5] Kless T(2012)Bisphosphonates for osteoporosis—where do we go from here? N Engl J Med 366 2048-1352

[6] Schmidt T(2004)Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography Bone 34 736-1199

[7] Steinle T(1999)Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group JAMA 282 1344-638

[8] Verheyen F(2004)Ten years’ experience with alendronate for osteoporosis in postmenopausal women N Engl J Med 350 1189-176

[9] Linder R(2008)Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women Cochrane Database Syst Rev 84 632-1841

[10] Hernlund E(2009)Adverse effects of bisphosphonates: implications for osteoporosis management Mayo Clin Proc 93 165-765